Experts Explain: Why This Phenomenon Only Occurs in Fraternal Twin Pregnancies, Never in Identical Twins

April 25, 2026 Dr. Michael Lee – Health Editor Health

A rare reproductive phenomenon captured global attention in early 2026 when a woman in Spain became pregnant with twins while already carrying a fetus—a condition medically termed superfetation. This extraordinary event, occurring in approximately one in several million pregnancies, has reignited scientific inquiry into the biological mechanisms that typically prevent ovulation during pregnancy. While superfetation remains exceptionally uncommon, documented cases challenge long-held assumptions about hormonal regulation and endometrial receptivity, offering a unique window into human reproductive plasticity.

Key Clinical Takeaways:

  • Superfetation occurs when a second ovulation and fertilization happen during an existing pregnancy, resulting in fetuses of different gestational ages.
  • It’s biologically plausible only in dizygotic (fraternal) twin pregnancies due to continued ovarian activity, never in monozygotic (identical) conceptions.
  • Although exceedingly rare, awareness of superfetation is critical for accurate prenatal dating and management to avoid misinterpretation of fetal growth discrepancies.

The case, first reported by clinicians at Hospital Universitario La Paz in Madrid, involved a 32-year-old woman undergoing fertility treatment who presented with discordant fetal sizes on routine ultrasound. Subsequent monitoring confirmed two embryos with a four-week developmental difference, consistent with superfetation rather than asynchronous growth in a single gestation. Experts emphasized that this phenomenon can only arise when hormonal suppression of the hypothalamic-pituitary-ovulatory axis fails—typically due to exogenous gonadotropin use in assisted reproductive technologies (ART)—allowing a secondary follicle to mature and ovulate despite elevated progesterone and human chorionic gonadotropin (hCG) levels from the initial pregnancy.

“Superfetation is not a failure of nature but a rare breach in its usually robust safeguards. In the context of ART, where we pharmacologically stimulate ovulation, we must remain vigilant for atypical presentations that challenge standard dating assumptions.”

— Dr. Elena Rojas, Reproductive Endocrinologist, Instituto Valenciano de Infertilidad (IVI)

Historically, fewer than 20 confirmed cases of superfetation have been published in medical literature since the 19th century, with most occurring in association with ovulation-inducing therapies. A 2021 review in Fertility and Sterility analyzed 11 verified instances, noting a strong correlation with gonadotropin-releasing hormone (GnRH) agonist protocols used in in vitro fertilization (IVF). The Madrid case aligns with this pattern, as the patient had undergone controlled ovarian stimulation prior to conception. Unlike superfecundation—where two ova from the same menstrual cycle are fertilized by separate acts of intercourse—superfetation involves a true temporal gap in conception, making it a distinct pathophysiological entity.

Clinically, the primary concern lies in accurate gestational age assignment. Misinterpreting the younger twin as growth-restricted could lead to unnecessary interventions, including premature delivery or invasive testing. Serial ultrasounds every two to three weeks, combined with maternal serum markers when appropriate, are recommended to track differential growth trajectories. Amniocentesis or chorionic villus sampling may be considered if genetic disparities are suspected, though zygosity confirmation typically requires postnatal analysis.

“In cases of suspected superfetation, the goal is not to prevent the pregnancy but to understand its unique timeline. Precision dating avoids iatrogenic harm and supports informed decision-making for both obstetricians and families.”

— Dr. Samuel Greene, Maternal-Fetal Medicine Specialist, Mayo Clinic

From a public health perspective, superfetation underscores the need for individualized monitoring in ART pregnancies. While the overall incidence remains negligible—estimated at 0.0003% of pregnancies based on European ART registry data—clinics utilizing aggressive stimulation protocols should consider routine early ultrasounds to detect atypical implantation patterns. This vigilance supports the broader goal of reducing perinatal morbidity through early identification of atypical gestational presentations.

For patients navigating complex fertility journeys or experiencing unexpected prenatal findings, consultation with specialists in reproductive endocrinology and maternal-fetal medicine is essential. Facilities equipped for advanced fetal assessment and genetic counseling provide critical support in distinguishing superfetation from other causes of fetal discordance. Those seeking expert evaluation can connect with vetted reproductive endocrinologists and maternal-fetal medicine specialists through our accredited network. genetic counseling centers offer invaluable guidance when interpreting prenatal screening results in atypical gestational scenarios.

As reproductive technologies advance, so too must our understanding of their biological boundaries. Superfetation, while a curiosity, serves as a reminder that human physiology retains subtle variances that can emerge under pharmacological influence. Continued case reporting and registry-based research will refine risk stratification and improve counseling for individuals undergoing ovulation induction—ensuring that innovation in assisted reproduction remains grounded in both scientific rigor and patient safety.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*

,